Eli Lilly and Company
For nearly 150 years, we’ve made significant and game-changing progress on our mission to make life better for people around the world. We’ve remained headquartered in Indianapolis, Indiana, since our founding on May 10, 1876, but our employees now work in countries around the world.
And thanks to the dedication of our diverse global team, we’ve been able to answer the call for new medicines to help solve some of the world’s most significant health challenges
When you’re on a mission to do what’s never been done before, you seek people willing to challenge the status quo of medicine. Those willing to relentlessly pursue what’s next, all in the name of health above all. #WeAreLilly
We are Lilly
Why do our employees love coming to work each and every day? Here’s what they have to say.
47,000 global employees coming together from diverse backgrounds to create medicines that make life better for people around the world. Get to know Team Lilly through our Powered by Purpose series.
NEWS
It was a busy week for clinical trial announcements. Take a look.
Eli Lilly and Company is in the news with positive Olumiant data in COVID-19, a drop in COVID-19 product sales for the quarter and a protest of one of their ads. Here’s a look.
Eli Lilly and Company presented data analysis from the Phase II TRAILBLAZER-ALZ study at the Alzheimer’s Association International Conference (AAIC) that supports the argument that decreases in beta-amyloid in Alzheimer’s disease slows cognitive decline.
As COVID-19 infections continue to increase in the U.S., the FDA has expanded the EUA for Eli Lilly’s monoclonal antibody to include treatment with or without remdesivir.
The two companies announced their exclusive collaboration that will harness Kumquat’s small molecule immuno-oncology platform’s capabilities to discover novel clinical candidates.
While modern-day science has provided the world with highly effective vaccines to fight the COVID-19 pandemic, researchers have had less luck finding effective treatment options for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
The FDA’s ODAC met to discuss retifanlimab and voted 13-4 that a regulatory decision for the drug for this indication should be deferred until more data was available.
Why not take advantage of the perks of a lower cost of living, slower pace, and opportunities to make a big impact in some important disease areas?
The antibody is still being evaluated in clinical studies, with a large-scale Phase III trial expected to wrap in the second half of 2022.
JOBS
IN THE PRESS